Stifel on Viridian (VRDN): 'We view positive REVEAL-2 chronic TED data in 2Q26 as important'
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $48.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst comments "AMGN ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
